share_log

Harmony Biosciences | 8-K: HARMONY BIOSCIENCES REPORTS STRONG FIRST QUARTER FINANCIAL RESULTS AND ACCELERATION OF ITS GROWTH STRATEGY; ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES

Harmony Biosciences | 8-K: HARMONY BIOSCIENCES REPORTS STRONG FIRST QUARTER FINANCIAL RESULTS AND ACCELERATION OF ITS GROWTH STRATEGY; ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES

Harmony Biosciences | 8-K:HARMONY BIOSCIENCES公布了强劲的第一季度财务业绩和增长战略的加速;推进了PITOLISANT的特许经营权,将收入潜力扩大到2040年以后;加强睡眠/觉醒领导力,实现多元化发展,涉足罕见癫痫
美股SEC公告 ·  2024/04/30 19:50
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息